Kornimate/medical-research-clean huggingface dataset:
study of covalent menin inhibitor bmf-219 in adult patients with kras driven non-small cell lung cancer, pancreatic cancer, and colorectal cancer

Conditions: Non Small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; NSCLC; PDAC; CRC; Relapsed Cancer; Refractory Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Stage III Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Stage III Colorectal Cancer; Stage IV Colorectal Cancer; Stage III NSCLC; Stage IV NSCLC; KRAS Mutation-Related Tumors

Summary: a phase 1/1b dose finding study to determine the obd(s) and rp2d(s) of bmf-219, a covalent menin inhibitor small molecule, in subjects with kras mutated unresectable, locally advanced, or metastatic nsclc (cohort 1), pdac (cohort 2), and crc (cohort 3).

this is a dose finding study to determine the safety and tolerability, pharmacokinetics and pharmacodynamics, and clinical activity of escalating doses of bmf-219 administered orally (po) either once daily (qd) or twice daily (bid) in 28-day cycles. after observing acceptable safety performance in these dosing regimens, additional subjects will be enrolled to assess efficacy in the determination of the obd for use as a rp2d.

Eligibility criteria:
inclusion criteria 1. adults with a confirmed diagnosis of unresectable, locally advanced and/or metastatic stage iiib/iv nsclc, stage iii/iv pdac and/or stage iii/iv crc with no curative-intent treatment options and documented activating kras mutation (without known additional actionable driver mutations such as egfr, alk or ros1) 2. documented progression and measurable disease after ≥ 1 prior line of systemic therapy (≥ 2 and ≤ 4 prior lines for nsclc) with adequate washout period and resolution of treatment-related toxicities to ≤ grade 2 3. ecog ps of 0-2 (0-1 for pdac) and a life expectancy \> 3 months in the opinion of the investigator 4. adequate hematological, liver, and renal function 5. men and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment exclusion criteria 1. symptomatic and/or untreated cns or brain metastasis, pre-existing ild or pericardial/pleural effusion of ≥ grade 2 or requiring chronic oxygen therapy for copd or pleural effusions 2. serious concomitant disorder including infection 3. known positive test for hiv, hcv, hbv surface antigen 4. concurrent malignancy in the previous 2 years 5. prior menin inhibitor therapy 6. requiring treatment with a strong or moderate cyp3a inhibitor/inducer 7. significant cardiovascular disease or qtcf or qtcb prolongation. 8. major surgery within 4 weeks prior to first dose 9. women who are pregnant or lactating.

Keywords: oral covalent menin inhibitor relapsed refractory irreversible menin inhibitor menin inhibitor unresectable locally advanced metastatic menin menin therapy kras kras mutated
smart program impact on quality of life in inflammatory bowel diseases

Conditions: Inflammatory Bowel Diseases; Stress

Summary: this research study is being done to look at the impact of a stress management and resilience training (smart) program on the quality of life and healthcare utilization of patients with inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * history of ibd defined by a physician global assessment (pga) of quiescent, mild, moderate, or severe disease. * access to internet/device such as smart phone, tablet, or computer * patient reports stress as a trigger to their gi symptoms exclusion criteria: * corticosteroids in the previous 3 months * elicit substance use (including medical marijuana)
early identification and action in ckd

Conditions: Chronic Kidney Disease; Hypertension

Summary: chronic kidney disease (ckd) is highly prevalent and associated with significantly increased risk of cardiovascular morbidity and end-stage renal disease. evidence from randomized clinical trials suggests that treating urinary albumin excretion (uae), dyslipidemia, and hypertension will reduce these risks. unfortunately, less than 30% of the ckd population is screened and treated according to recommended guidelines. using a cluster-randomized, controlled design and clinic-embedded pharmacists, this pilot pragmatic trial will randomize 6 geisinger primary care clinics (72 patients) to usual care (group 1) or a pharmacist-directed "ckd action plan" (group 2). determining the impact of the ckd action plan on screening and treatment guideline adherence is the primary goal of this pilot study.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * egfrcr value between 45-59 ml/min/1.73m2 in the prior 12 months * scheduled laboratory appointment for serum creatinine testing within the next 30 days * average systolic or diastolic blood pressure reading of at least 150 or 85 mm hg, respectively, during the prior 12 months. exclusion criteria: * fewer than 2 blood pressure readings in the prior 12 months, * pregnancy * current hospitalization * life expectancy less than 6 months as determined by the study investigators

Keywords: chronic kidney disease albuminuria hypertension dyslipidemia cardiovascular disease pragmatic trial cluster randomized trial
periodontal infection and prematurity study

Conditions: Periodontal Diseases; Premature Birth

Summary: this research project is a multi-center double-blind, parallel, randomized, controlled clinical trial design comparing the efficacy of dental scaling and root planing to control treatment (superficial cleaning) for the prevention of preterm birth in pregnant women with periodontal disease.


Eligibility criteria:
inclusion criteria: * gestational age between 6 and 20 completed weeks exclusion criteria: * periodontal treatment during the pregnancy * antibiotic use within 2 weeks of enrollment * use of antimicrobial mouthwash within 2 weeks * multiple gestation * known mitral valve prolapse

Keywords: dental scaling
adaptive symptom care using fish-based nutritional directives post breast cancer

Conditions: Fatigue; Depression; Pain; Sleep Disturbance; Stress; Survivorship; Breast Cancer; Dietary Habits

Summary: inflammation has been consistently associated with psychoneurological symptoms (pns) among breast cancer survivors (bcs). evidence supporting interventional strategies promoting symptom-self management in reducing inflammation-induced pns in bcs is limited. current guidelines for bcs encourage the consumption of foods rich in omega-3 fatty acids. the omega-3 fatty acid docosahexaenoic acid (dha), abundantly available in fish, has a role in inflammatory downregulation. low dietary dha has been associated with inflammation and fatigue in bcs. dietary planning targeting increased fish consumption thereby reducing red and processed meats are components of the major nutritional recommendations for bcs. a critical gap exists in knowledge regarding interventions promoting adherence to dietary guidelines in bcs supporting pns self-management. this investigation uses personalized meal planning among bcss (n=150) who are 1-2 years post-treatment for early-stage breast cancer and experiencing pns (pain, fatigue, depression, sleep disturbance, stress) to evaluate the feasibility of a personalized meal planning approach in supporting adherence to current dietary guidelines for bcs. as a first step in this program of research, we will evaluate the feasibility of an personalized meal planning approach in promoting adherence to dietary guidelines for bcs through evaluating the feasibility of a personalized meal planning approach in a cohort of bcss with respect to recruitment, group allocation, salivary inflammatory quantification and receptivity to and adherence with dietary interventions. this investigation will also contribute to a preliminarily evaluation of the efficacy of high or low fish diet in reducing inflammation (il-1β, il-6, tnf-a) and pns symptoms. nationally, there is a priority for the development of personalized health strategies supporting self-management of adverse symptoms. this investigation focused on pns in bcs is an initial step in generating new knowledge in efficacious approaches toward guiding decisions on dietary behavior change strategies that are personalized, cost-effective, and sustainable.


Eligibility criteria:
inclusion criteria: * diagnosed with bca between 1 and 2 years prior to study enrollment * completed chemotherapy (except tamoxifen/aromatase inhibitors) and/or radiation * no evidence of cancer recurrence; * no chronic medical conditions involving the immune system or regular use of immunosuppressive medications; * no history of previous chemotherapy or cancer * no diagnosis of dementia or active psychosis; * 30-75 years of age * able/willing to sign informed consent. exclusion criteria: * women not meeting the inclusion criteria above; * non english-speaking

Keywords: breast cancer survivor dietary omega-3 intervention psychoneurological symptoms
neuromuscular balance in low back pain

Conditions: Low Back Pain

Summary: the research was an interventional study with a quantitative board, fulfilled in a private clinique specialized in trauma service; it was formed between august to october of 2006. the objective was to investigate the effectiveness of neuromuscular balance in lumbar pain. the 12 patients, with age between 20 and 55 years, whose did five consultations, with 100% presence, got relief of the pain and increase of movement of hips' articulation which was the most painful movement with 91,66% graduation. all the patients presented the shorting test positive and it kept positive in 7 patients. there was a significant improvement in pain relief (p=0,001,) comparing the first and the fifth consultation, and hip articulation movement. even after the relief of the pain, 7(58,3%) of the patients kept the treatment for a more effective rehabilitation and prevention of repetition of the symptoms. it was concluded that the neuromuscular balance relieved quickly the pain, being essential for effective rehabilitation of low back pain, with the inclusion of others manual techniques.

the low back pain is a symptom presented in muscle-skeletal change on lumbar region, preferring young adults, in economic active fase. the neuromuscular balance was developed by soulier when he met the "activator methods" which was a pen that create vibrations and consist in a vibration or a micro thrust to reduce the articulation and spinal problems through a non manipulative correction. the research was un interventional study with a quantitative board, fulfilled in a private clinique specialized in trauma service; it was formed between august to october of 2006. the objective was to investigate the effectiveness of neuromuscular balance in lumbar pain. the 12 patients, with age between 20 and 55 years, whose did five consultations, with 100% presence, got relief of the pain and increase of movement of hips' articulation which was the most painful movement with 91,66% graduation. all the patients presented the shorting test positive and it kept positive in 7 patients. there was a significant improvement in pain relief (p=0,001,) comparing the first and the fifth consultation, and hip articulation movement. even after the relief of the pain, 7(58,3%) of the patients kept the treatment for a more effective rehabilitation and prevention of repetition of the symptoms. it was concluded that the neuromuscular balance relieved quickly the pain, being essential for effective rehabilitation of low back pain, with the inclusion of others manual techniques.

Eligibility criteria:
inclusion criteria: * patients with low back pain between 20 and 55 years old, submitted to a physical therapy treatment. exclusion criteria: * patients with no miofascial low back pain

Keywords: low back pain physical therapy pain
preoperative intravesical electromotive mitomycin-c for primary non-muscle invasive bladder cancer

Conditions: Superficial Bladder Cancer

Summary: early single instillation of chemotherapy after tur is recommended in the european association of urology guidelines. nevertheless, the procedure is suboptimal for patients with multiple tumors, sometimes is not tolerated and it can results in severe complications. in both laboratory and clinical studies, intravesical electromotive drug administration (emda) increases mitomycin-c (mmc) bladder uptake, resulting in an improved clinical efficacy in non-muscle invasive bladder cancer (nmibc). the investigators will compare the effects of one immediate pre-tur intravesical emda/mmc instillation with one immediate post-tur intravesical passive diffusion mmc (pd/mmc) instillation and tur alone in patients with nmibc. all eligible patients with primary nmibc will be randomized into 3 groups who will undergo transurethral resection alone (tur/alone); tur plus single immediate postoperative instillation (immediately after tur) of 40 mg pd/mmc with a dwell time of 60 minutes; or single immediate preoperative instillation (immediately before tur) of 40 mg emda/mmc with 20 ma electric current for 30 minutes. patients with intermediate and high risk nmibc will undergo adjuvant intravesical therapy. the primary end points will be the recurrence rate and disease-free interval. all clinical analyses will be performed on an intent to treat basis.


Eligibility criteria:
inclusion criteria: * all patients with primary histologically proven stage pta-pt1 transitional-cell carcinoma of the bladder exclusion criteria: * previous treatments with bacillus calmette-guerin, mitomycin-c, or with any other intravesical cytostatic agent * concomitant urothelial tumours of the upper urinary tract * previous or concomitant muscle-invasive (ie, stage t2 or higher) transitional-cell carcinoma of the bladder * bladder capacity less than 200 ml * untreated urinary-tract infection * disease of upper urinary tract * previous radiotherapy to the pelvis * other concurrent chemotherapy * treatment with radiotherapy-response or biological-response modifiers * other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma) * pregnancy or nursing * and psychological, familial or sociological factors that would preclude study participation

Keywords: intravesical chemotherapy early single instillation mitomycin-c electromotive drug administration
effect of progesterone levels on 15th day after embryo transfer in early miscarriage < 7 wg or evolving pregancy rates

Conditions: ART

Summary: progesterone level has been studied at days before embryo transfert. but, progesterone blood level has not been studied 15 days after embryo transfert. the aim of this study is to study progesterone level impact at 15 days after embryo transfert on evolving pregnanies or early miscarriages.


Eligibility criteria:
inclusion criteria: * art program in montpellier hospital * age \>18 years old * blood progesterone level 15 days after embryo transfert * pregnancy development know exclusion criteria: - non uterine pregnancy

Keywords: betahcg + pregnancy development know progesterone level miscarriage
phase ⅱ study of intercostal nerve block with hr18034 for postsurgical pain management

Conditions: Thoracoscopic Lobectomy

Summary: phase ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection intercostal nerve block with hr18034 for postoperative pain management compared with ropivacaine.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. scheduled to undergo thoracoscopic lobectomy under general anesthesia. 3. male or female, aged 18 years and older inclusive 4. body mass index (bmi) 18-30 kg/m2 inclusive 5. american society of anesthesiologists (asa) physical status classification ⅰ\~ⅱ exclusion criteria: 1. subjects with a history of new myocardial infarction or unstable angina within 6 months prior to randomization; 2. subjects with a history of ischemic stroke or transient ischemic attack (tia) 3. subjects with a history of mental system diseases and cognitive dysfunction 4. combination of other pain conditions that may affect postoperative pain assessment 5. combination with ventilation disorders caused by airway or spinal anatomical factors, bronchiectasis, and severe chest adhesions on the surgical side 6. clinically significant abnormal clinical laboratory test value 7. allergic to a drug ingredient or component 8. use of any of medications, which affect drug metabolism or analgesia evaluation, within 5 half-lives or as specified prior to the study surgical procedure 9. history of alcohol abuse or prescription and/or illicit drug abuse 10. subjects with special diets (including tobacco, grapefruit and caffeine) 11. pregnant or nursing women 12. no birth control during the specified period of time 13. participated in clinical trials of other drugs (received experimental drugs) 14. the inestigators determined that other conditions were inappropriate for participation in this clinical trial
effects of remifentanil infusion on emergence delirium after dental surgery in children

Conditions: Emergence Delirium

Summary: in this study, the investigators tried to show the effect of remifentanil on emergence delirium caused by sevoflurane used in general anesthesia.we planned a retrospective study. we formed two groups of 80 participants. one group included patients who were received remifentanil infusion during general anesthesia.the other group included patients who were received only sevoflurane inhalation anesthesia. the patients included in the study were evaluated for emergence delirium in the postoperative period be evaluating the past recorded informations.


Eligibility criteria:
inclusion criteria american society of anesthesiologists score 1-2 - exclusion criteria: * neurological disease, psychiatric illness
urodynamic evaluation in patients after spinal cord injury

Conditions: Spinal Cord Injuries; Neurogenic Bladder; Urodynamics

Summary: retrospective study, which analyzed 100 medical histories of patients who were admitted o the neurological rehabilitation ward of the rehabilitation clinic in the orthopedic-rehabilitation hospital in poznan in years 2010-2019.

all patients considered for the study underwent routine testing: blood counts, urinalysis, urine culture, and sensitivity.

Eligibility criteria:
inclusion criteria: * incomplete spinal cord injuries, * the results of the urodynamic testing (conducted by the same urologist) by admission, * urine culture test by admission. exclusion criteria: * complete spinal cord injury * without urodynamic test in medical documentation by admission, * without urine culture test by admission, * with symptomatic urinary tract infection in urodynamic test

Keywords: urodynamics
urothelial cancer tumor bio-markers and physical-spectroscopic characteristic

Conditions: Urothelial Carcinoma; Bladder Cancer; Urothelial Neoplasm; Urothelial Carcinoma Bladder; Urothelial Carcinoma in Situ

Summary: our multicenter observational study is a non-profit prospective study. the study was born from the amplitude project, which comprise the sod of minimally invasive robotic urological surgery and renal transplants of aou careggi with the university of florence, as well as with the national research council (cnr) and the university of milan bicocca (unimib) the study consists of a phase of enrollment of patients who will be admitted to the sod of mini invasive robotic urological surgery and renal transplantation of aou careggi. enrollment in the study does not alter normal clinical practice and does not involve additional risks for patients. patients will have to meet the inclusion and exclusion criteria of the study and will be enrolled sequentially, until the established sample size is reached. patients undergoing surgery for the removal of bladder neoplasm, be it endoscopic or surgical with radical intent (cystectomy), will be taken a fragment of tumor bladder tissue, on which histopathological analysis will be performed. in patients undergoing radical cystectomy only, a fragment of healthy urothelial tissue, free from neoplasia, will also be removed. the samples will be performed in patients under general and / or spinal anesthesia in case of turb, thus not causing pain or discomfort to the patient, or ex-vivo on the operative piece in case of radical cystectomy, without causing further damage or pain to the patient. from these samples, specially stored in solutions that keep their characteristics unaltered, a 3d culture model (organoid) will be obtained both from cells obtained from bladder cancer and from healthy tissue on which biomolecular, metabolomic and spectroscopic characterization studies will be tested and carried out. with a view to staging and grading bladder neoplasia.


Eligibility criteria:
inclusion criteria: * age\>18 years * bladder cancer diagnosis * capability to express informed consent exclusion criteria: * age under 18 * pregnancy * lack of informed consent * inability to provide informed consent

Keywords: spectroscopy bladder cancer urothelial carcinoma tumor biomarkers metabolomic proteomic
randomized controlled trial comparing drains usage vs without drains after thyroid surgery

Conditions: Thyroid Surgery; Drains; Post Thyroidectomy Complications

Summary: the aim of this study is to compare patients who used drain to patients who did not use drain post-thyroidectomy regarding the short-term outcomes .


Eligibility criteria:
inclusion criteria: * (1) male or female patients undergoing thyroidectomy (2) patients with ages: from 18 to 60 years old. (3) patients with normal thyroid function tests (4) patients who are fit for general-anesthesia. exclusion criteria: * (1) patients with bleeding diathesis and those on anticoagulants. (2) patients with thyrotoxicosis (uncontrolled) (3) patients those requiring neck l.n dissection. (4) patients with previous neck surgeries. (5) patients with severe comorbid conditions with high risk for general anesthesia.
a study to evaluate the safety, tolerability and effectiveness of the renew insert in treating accidental bowel leakage

Conditions: Bowel Incontinence

Summary: the purpose of this study is to determine whether the use of the renew insert is effective, tolerable and safe in the treatment of accidental bowel leakage due to bowel incontinence.

prospective, open label, single-arm, non-randomized, multi-center study designed to evaluate the efficacy, safety and tolerability of the renew insert in moderate-to-severe bowel incontinence patients: minimum wexner score of 12 and at least weekly (score 3 or higher) leakage of solid and or liquid type stool.

Eligibility criteria:
inclusion criteria: * signed informed consent * minimum wexner bowel incontinence score of 12 and at least weekly (score of 3 or higher) leakage of solid and/or liquid type stool, with no greater than 50% of subjects with daily (score 4) of uncontrolled gas. * patients colon surveillance must be in compliance with american cancer society colon screening guidelines. if patient is out of compliance, they may be scheduled for colonoscopy. * patient comprehends study meaning \& is capable of carrying out study duties * fluent in english exclusion criteria: * american society of anesthesiologist (asa) score of 4 or higher * spinal cord injury or other major neurological diagnosis * known immune deficiency state * significant cardiac arrhythmia * pregnant or breastfeeding * inflammatory bowel disease * requirement of medication delivered by suppository * active perianal abscess or fistula * present rectal prolapse * third degree hemorrhoids * anal stricture * history or rectal spasm * rectal surgery in past 6 months * unresolved anismus * fecal impaction with overflow diarrhea * ileo-anal pouch * rectocele requiring surgery * allergy to silicone or one of its components * significant medical condition which interferes with study participation

Keywords: incontinence bowel movement fecal anal diarrhea stool rectal feces uncontrolled loose leakage rectum bm watery urgent flatulence gas